LADENBURG THALM/SH SH lowered shares of Athenex (NASDAQ:ATNX – Get Rating) from a buy rating to a neutral rating in a research report report published on Tuesday, The Fly reports. Athenex Stock Performance Shares of ATNX stock opened at $1.39 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 1.00 […]
Athenex, Inc. (NASDAQ:ATNX – Get Rating) – Equities research analysts at SVB Leerink lifted their FY2023 earnings estimates for shares of Athenex in a research report issued to clients and investors on Monday, March 20th. SVB Leerink analyst J. Chang now forecasts that the company will earn ($1.45) per share for the year, up from […]
Athenex (NASDAQ:ATNX – Get Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03, MarketWatch Earnings reports. Athenex had a negative return on equity of 105.66% and a negative net margin of 166.68%. During the same period in the prior year, […]
Zacks Investment Research cut shares of Athenex (NASDAQ:ATNX – Get Rating) from a buy rating to a hold rating in a research note published on Friday, Zacks.com reports. According to Zacks, “Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company’s […]
Zacks Investment Research upgraded shares of Athenex (NASDAQ:ATNX – Get Rating) from a hold rating to a buy rating in a research report released on Monday, Zacks.com reports. Zacks Investment Research currently has $1.00 price target on the stock. According to Zacks, “Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery […]